

Gabapentin withdrawal causing adrenergic toxidrome

A case report and literature review

January 27, 2015 · Case Reports and Clinical Pearls

Vikas K. Singh MD¹, Obiomachukwu Chukwurah MD¹, Alycia Petraglia DO¹, Khaled Fernainy MD²

¹ University of Pittsburgh Medical Center McKeesport, ² University of Pittsburgh School of Medicine

Singh VK, Chukwurah O, Petraglia A, Fernainy K. Gabapentin withdrawal causing adrenergic toxidrome: A case report and literature review. PulmCCM Journal. 2015 Jan 27 [last modified: 2015 Jan 31]. Edition 1.

Abstract

Gabapentin is an anticonvulsant most often prescribed for off-label indications, such as neuropathic pain. Rarely, an adrenergic toxidrome may occur after discontinuation of gabapentin. We describe a case of gabapentin withdrawal precipitating an autonomic hyperactive state which resolved with administration of gabapentin. Gabapentin withdrawal should be considered in patients presenting with unexplained autonomic hyperactivity after abrupt discontinuation of chronic gabapentin, especially at higher doses.

Funding Statement

No external funding was provided; none of the authors have any conflicts of interest to declare.

Introduction

Gabapentin was approved by United States Food and Drug Administration (FDA) in 1993 as an adjunctive therapy for partial seizure, and is also indicated for treatment of postherpetic neuralgia.¹ Since its introduction, “off-label” use of gabapentin (marketed as Neurontin®, Gralise®, Horizant®, and Fanatrex®) has eclipsed its approved uses. Of gabapentin’s brand-name \$2.3 billion in sales in 2002, \$2.1 billion were asserted to have been for off-label use; up to 95% of gabapentin doses are prescribed for unapproved uses such as neuropathic pain.^{1·2·3·4}

Gabapentin was designed as a lipophilic GABA agonist, but it does not act directly on GABA receptors in in vitro experimental models and its exact mechanism of action is not clear.⁵ Gabapentin is not protein bound and is excreted unchanged, mainly in urine.³

Since the first case report of gabapentin withdrawal in 2001 with autonomic hyperactivity, 13 case reports describing gabapentin withdrawal have been reported.⁶ We present a case of gabapentin withdrawal with an adrenergic toxidrome presentation, and review previous published cases. We used a PubMed search with the MeSH terms “gabapentin” and “gabapentin withdrawal”.

Case Presentation

Our case, a 57 year old female with a history of rheumatoid factor positive rheumatoid arthritis on tocilizumab, sicca syndrome, HTN, lower back pain and neuropathic pain in lower extremities, allergy to naproxen presented with anaphylactic reaction to Aleve (naproxen). She was not aware that Aleve is naproxen and took it for headache. She presented with angioedema and anaphylaxis manifesting as worsening generalized itching, difficulty in swallowing, tongue swelling and wheezing. She received IM epinephrine, IV methylprednisolone and IV diphenhydramine and ultimately needed intubation to maintain airway. She was maintained on propofol infusion and prn fentanyl and lorazepam during mechanical ventilation. After 36 hours of intubation her angioedema had subsided and she was extubated without issues.

Within 2 hours, her post-extubation period was complicated by hyperactive delirium with autonomic hyperactivity (tachycardia, hypertension, diaphoresis and tachypnea). She failed to respond to repeated IV lorazepam and IV haloperidol. Discussion with close family confirmed that she does not drink alcohol on any regular basis – she had been abstinent due to her use of Methotrexate for rheumatoid arthritis. Review of home medication raised the possibility of gabapentin withdrawal. She was on gabapentin 800mg qid. Her other home medication were HCTZ, amitriptyline, tramadol, MDI albuterol and cevimeline. Her routine labs and imaging studies were unremarkable.

Gabapentin resumption was complicated as it is not available in IV, IM or per-rectal preparation and patient because of delirium and agitation was not cooperative enough to take oral medication. We were finally able to administer a single dose of 300 mg of gabapentin. Within hours of the first dose delirium started improving, and symptoms resolved completely within 6 hours. She was discharged home next day in calm, coherent and stable condition.

Discussion and Clinical Pearls

In review of published cases most of the cases were on high doses of gabapentin (1200mg or higher) and had a wide variability in duration of therapy, range 1 month to 60 month (Table-1). Most of the cases (~75%) had abrupt discontinuation of gabapentin and early onset of withdrawal symptoms. Early onset of withdrawal symptom could be explained by the short half-life (5-7 hours) of drug. Gabapentin withdrawal symptoms are similar to alcohol and benzodiazepine withdrawal but gabapentin withdrawal does not respond to benzodiazepines. In most of the cases initiation of gabapentin was delayed and could be due to lack of awareness of gabapentin withdrawal. Patients will benefit from early recognition of gabapentin withdrawal as prompt resolution (within hours) of withdrawal symptoms happens with gabapentin initiation. A patient on chronic gabapentin should have doses administered enterally, perhaps in lower doses, to decrease the risk of an abrupt discontinuation.

Table 1. Literature review of case reports of gabapentin withdrawal. (Click image or link to view full-size.)

Table-1. Description of published case report(s) of gabapentin withdrawal

PMID	Year	Age	Sex	Indication for Gabapentin	Daily dose, mg/day	Gabapentin duration, mnth	Abrupt Discontinuation	Symptom Onset, days	Autonomic Over activity				Gabapentin restart, days	Recovery onset, days	Failure with BZD	Failure with haloperidol
									Hypertension	Tachycardia	Tachypnea	Agitation/Delirium				
11479399(6)	2001	29	M	2	4800		Y	1	Y	Y	Y	Y	3	<1		
11479399(6)	2001	36	M	2	3600	2	Y	2	Y	Y	Y	Y	3	<1		
11479399(6)	2001	28	M	3	2400	6	Y	2	N	N	N	Y	2			
12507063(7)	2002	34	M	1	8000	9	Y	4				Y			Y	
15898970(8)	2005	81	F	2	800	60	N	4	Y				10	2	Y	
17388722(9)	2007	33	M	2	3600		Y	3		Y		Y	3	2	Y	Y
17388722(9)	2007	63	M	1	4900		Y		Y				6	<1	Y	
17327964(10)	2007	67	F	1	7200		Y					Y				
20484214(11)	2010	53	F	1	700		Y	3		Y		Y	5	<1	Y	
20718643(12)	2010	41	M	3	1200			<1				N	2	1		
21652784(13)	2011	76	F	1	3600	1	N				Y	Y	2	<1	Y	
24028370(14)	2013	75	F	1	1800		N	11	Y	Y		Y		3	Y	
23427359(15)	2013	76	F	1	900	24	Y	1				Y				N

PMID-PubMed ID of case reports; Year-Year in which case reports were published; Sex-M(male), F(Female); Indication-1(Neu Disorders), 3(Others or not mentioned in case reports), BZD-benzodiazepine, Y-Yes, N-No

References

1. Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed medicaid population. *J Manag Care Pharm.* 2002 Jul-Aug;8(4):266-71. PubMed PMID:14613419.
REFERENCE LINK
2. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. *Arch Intern Med.* 2006 May 8;166(9):1021-6. PubMed PMID:16682577.
REFERENCE LINK
3. Gabapentin for pain: New evidence from hidden data. *Therapeutics Letter* 2009 [cited 2014 May-11-2014]
REFERENCE LINK
4. Evans, D. "Pfizer Broke the Law by Promoting Drugs for Unapproved Uses," Bloomberg [Internet at <http://www.bloomberg.com/apps/news?pid=newsarchive&sid=a4yV1nYxCGoA>]
REFERENCE LINK
5. McNamara JO. Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 12th ed., ch. 21: Pharmacotherapy of the epilepsies; 2011.
REFERENCE LINK
6. Norton JW. Gabapentin withdrawal syndrome. *Clin Neuropharmacol.* 2001 Jul-Aug;24(4):245-6. PubMed PMID:11479399.
REFERENCE LINK